Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design

VG Atkinson; A Hauschild; GV Long; M Mandala; M Kicinski; AS Govaerts; I Klauck; M Ouali; PC Lorigan; AMM Eggermont; ACJ van Akkooi

Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design

VG Atkinson
, A Hauschild
, GV Long
, M Mandala
, M Kicinski
, AS Govaerts
, I Klauck
, M Ouali
, PC Lorigan
, AMM Eggermont
, ACJ van Akkooi

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	115-115
Number of pages	1
Journal	Asia-Pacific Journal of Clinical Oncology
Volume	18
Publication status	Published - Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Atkinson, VG., Hauschild, A., Long, GV., Mandala, M., Kicinski, M., Govaerts, AS., Klauck, I., Ouali, M., Lorigan, PC., Eggermont, AMM., & van Akkooi, ACJ. (2022). Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. Asia-Pacific Journal of Clinical Oncology, 18, 115-115.

@article{e682d36c2951414f839e992374025904,

title = "Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design",

author = "VG Atkinson and A Hauschild and GV Long and M Mandala and M Kicinski and AS Govaerts and I Klauck and M Ouali and PC Lorigan and AMM Eggermont and \{van Akkooi\}, ACJ",

year = "2022",

month = nov,

language = "English",

volume = "18",

pages = "115--115",

journal = "Asia-Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "John Wiley \& Sons Ltd",

}

Atkinson, VG, Hauschild, A, Long, GV, Mandala, M, Kicinski, M, Govaerts, AS, Klauck, I, Ouali, M, Lorigan, PC, Eggermont, AMM & van Akkooi, ACJ 2022, 'Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design', Asia-Pacific Journal of Clinical Oncology, vol. 18, pp. 115-115.

TY - JOUR

T1 - Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma

T2 - COLUMBUS-AD study design

AU - Atkinson, VG

AU - Hauschild, A

AU - Long, GV

AU - Mandala, M

AU - Kicinski, M

AU - Govaerts, AS

AU - Klauck, I

AU - Ouali, M

AU - Lorigan, PC

AU - Eggermont, AMM

AU - van Akkooi, ACJ

PY - 2022/11

Y1 - 2022/11

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000871956500012&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 1743-7555

VL - 18

SP - 115

EP - 115

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

ER -

Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design

UN SDGs

Other files and links

Cite this